Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and...
-
Vivasor Appoints JP3E Development as Exclusive Strategic Representative in the Republic of Korea
-
Austin, TX, USA, June 26, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “In Silico Clinical Trials Market Size, Trends and Insights By Component...
-
Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Bioprocess Digital Twin Market Size, Trends and Insights By Component...
-
Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Cell Therapy Human Raw Materials Market Size, Trends and Insights By Product Type...
-
Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Stem Cell Culture Media Market Size, Trends and Insights By Type (Mesenchymal...
-
Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.
-
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient...
-
Austin, TX, USA, June 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Next Generation Sequencing Services Market Size, Trends and Insights By Service...
-
Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug...